AG
SRNE

Aperio Group’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Aperio Group’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$248K Sell
36,362
-6,855
-16% -$55.1K ﹤0.01% 2251
2020
Q3 		$482K Buy
43,217
+15,317
+55% +$140K ﹤0.01% 1829
2020
Q2 		$175K Buy
27,900
+13,516
+94% +$51.7K ﹤0.01% 2203
2020
Q1 		$26K Buy
+14,384
New +$41.4K ﹤0.01% 2305
2019
Q3 		– Sell
-1,135
Closed -$3K – 2878
2019
Q2 		$3K Buy
+1,135
New +$4.08K ﹤0.01% 2907

Other funds holding SRNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Aperio Group's SRNE Position: Q4 2020 in Review

Aperio Group reduced its Sorrento Therapeutics, Inc. (SRNE) stake by 16% in Q4 2020, selling an estimated $55.1K and leaving 36,362 shares worth $248K. The position accounts for ﹤0.01% of the portfolio, ranked #2251.

Aperio Group first reported a position in SRNE in Q2 2019 and has held it in 5 quarters since. The position peaked at $482K in Q3 2020. 219 funds tracked by Wall St. Rank hold SRNE as of Q4 2020.

  • Aperio Group held 36,362 shares of Sorrento Therapeutics, Inc. worth $248K as of Q4 2020.
  • Aperio Group sold 6,855 Sorrento Therapeutics, Inc. shares in Q4 2020, an estimated $55.1K.
  • Sorrento Therapeutics, Inc. made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2251 holding.
  • Aperio Group first reported a position in Sorrento Therapeutics, Inc. in Q2 2019 and has held it in 5 quarters since.
  • Aperio Group's Sorrento Therapeutics, Inc. position peaked at $482K in Q3 2020.
  • 219 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.